MicroRNA‑27b inhibits the development of melanoma by targeting MYC
- Yi Tian
- Juanni Zeng
- Zongliang Yang
Affiliations: Department of Dermatology, The Second Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan 410005, P.R. China, Department of Anorectal Disease, The Second Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan 410005, P.R. China
- Published online on: March 12, 2021 https://doi.org/10.3892/ol.2021.12631
Copyright: © Tian
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Cutaneous malignant melanoma is a malignancy with one of the fastest increasing incidence rates worldwide; however, the mechanism underlying the occurrence and development of melanoma remains unclear. The aim of the present study was to identify novel biomarkers for the occurrence and development of melanoma. The results of the present study demonstrated that the expression levels of microRNA (miR)‑27b were decreased in melanoma tissue samples compared with those in adjacent noncancerous tissue samples and cells according to online and experimental data. By contrast, MYC expression levels were upregulated in melanoma compared with those in adjacent noncancerous tissue samples. miR‑27b overexpression significantly inhibited A375 and A2085 melanoma cell DNA synthesis, viability and invasive ability. Dual‑luciferase reporter assay results demonstrated that miR‑27b inhibited MYC expression through binding to the 3'‑untranslated region of MYC mRNA. MYC knockdown in melanoma cells exerted similar effects to those of miR‑27b overexpression on DNA synthesis, cell viability and invasive ability; the effects of miR‑27b inhibition were significantly reversed by MYC knockdown. In conclusion, the miR‑27b/MYC axis may modulate malignant melanoma cell biological behaviors and may be a potential target for melanoma treatment.